Last update: Aug. 7, 2019
Not risky for breastfeeding or infant.
A humanized monoclonal antibody (IgG1 immunoglobulin) produced by recombinant DNA technology.
It works by blocking the vascular endothelial growth factor.
Intravitreal administration is used in macular degeneration due to choroidal neovascularization.
It is excreted in breastmilk in clinically insignificant amounts (McFarland 2015, Ehlken 2012) and no problems have been observed in infants whose mothers had been given it (Mc Farland 2015, Tarantola 2010).
Intravitreal administration: the small dose and the minimal transfer to blood from the vitreous humor as well as there being no detected levels in breastmilk or side effects in infants make this type of administration safe during breastfeeding.
A study has recorded a 35% decrease in the concentration of vascular endothelial growth factor (VEGF) in breastmilk, without specifying problems in the infant, for this reason some authors recommend the use of ranibizumab which does not seem to decrease the concentration of VEGF (Ehlken 2012).
Given the strong existing evidence regarding the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother who wishes to continue with breastfeeding (Koren 2013).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.